Home › All Companies › AIDX › Annual Report

20/20 Biolabs, Inc. (AIDX) — Annual Report

AI-Powered SEC Filing Analysis

← All AIDX filings
Latest Annual Report Filed: 2026-03-31

Key Insights

  • 20/20 Biolabs, Inc. is a small, emerging growth company in the biopharma industry based in Gaithersburg, Maryland.
  • The company does not yet have a product on the market and its financial results show it is still in the early, pre-revenue stage of development.
  • Key risks facing the company include uncertainties around obtaining regulatory approval, securing sufficient funding, and competition in the biopharma space.
Sentiment: Neutral Significance: 5/10
View Original Filing →

Want the newest filings?

This analysis covers the filing from 2026-03-31. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Other reports for 20/20 Biolabs, Inc.

Current Report Insider Trading

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.